IE 11 is a very old Browser and it`s not supported on this site
Business Report Performance

Performance/Multi-year comparison

Indexed performance since launch

BB Biotech AG (SIX)-CHF


Rolling performance

 

 

SHARE

 

NAV

 

NBI TR

30.09.2021 – 30.09.2022

 

(33.7%)

 

(22.7%)

 

(21.3%)

30.09.2020 – 30.09.2021

 

31.1%

 

24.5%

 

21.9%

30.09.2019 – 30.09.2020

 

15.9%

 

21.0%

 

26.4%

28.09.2018 – 30.09.2019

 

(10.6%)

 

(14.1%)

 

(16.2%)

29.09.2017 – 28.09.2018

 

15.7%

 

0.2%

 

11.1%

Annual performance

 

 

SHARE

 

NAV

 

NBI TR

2021

 

8.3%

 

(11.5%)

 

3.0%

2020

 

19.3%

 

24.3%

 

15.8%

2019

 

18.5%

 

23.4%

 

23.0%

2018

 

(5.2%)

 

(14.5%)

 

(8.0%)

2017

 

22.9%

 

23.4%

 

16.4%

Cumulated performance

30.09.2022

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

(27.7%)

 

(9.9%)

 

(13.4%)

1 year

 

(33.7%)

 

(22.7%)

 

(21.3%)

3 years

 

0.7%

 

16.4%

 

21.3%

5 years

 

4.1%

 

0.2%

 

13.0%

10 years

 

350%

 

242%

 

179%

since inception 1)

 

2 209%

 

2 042%

 

1 196%

1 09.11.1993

Annualized performance

30.09.2022

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

(33.7%)

 

(22.7%)

 

(21.3%)

3 years

 

0.2%

 

5.2%

 

6.6%

5 years

 

0.8%

 

0.0%

 

2.5%

10 years

 

16.2%

 

13.1%

 

10.8%

since inception 1)

 

11.5%

 

11.2%

 

9.3%

1 09.11.1993

BB BIOTECH AG (XETRA)-EUR


Rolling performance

 

 

SHARE

 

NAV

 

NBI TR

30.09.2021 – 30.09.2022

 

(26.1%)

 

(13.9%)

 

(11.7%)

30.09.2020 – 30.09.2021

 

29.6%

 

24.5%

 

21.8%

30.09.2019 – 30.09.2020

 

17.5%

 

22.0%

 

27.3%

28.09.2018 – 30.09.2019

 

(5.8%)

 

(10.0%)

 

(12.6%)

29.09.2017 – 28.09.2018

 

15.5%

 

0.6%

 

12.1%

Annual performance

 

 

SHARE

 

NAV

 

NBI TR

2021

 

13.3%

 

(7.8%)

 

7.4%

2020

 

18.1%

 

24.8%

 

16.1%

2019

 

23.4%

 

28.1%

 

27.6%

2018

 

(2.2%)

 

(11.1%)

 

(4.3%)

2017

 

12.9%

 

12.5%

 

6.7%

Cumulated performance

30.09.2022

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

(22.4%)

 

(3.3%)

 

(6.7%)

1 year

 

(26.1%)

 

(13.9%)

 

(11.7%)

3 years

 

12.6%

 

30.9%

 

37.0%

5 years

 

22.4%

 

18.6%

 

34.2%

10 years

 

457%

 

328%

 

250%

since inception 1)

 

1 960%

 

1 823%

 

1 369%

1 10.12.1997

Annualized performance

30.09.2022

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

(26.1%)

 

(13.9%)

 

(11.7%)

3 years

 

4.0%

 

9.4%

 

11.1%

5 years

 

4.1%

 

3.5%

 

6.1%

10 years

 

18.7%

 

15.6%

 

13.3%

since inception 1)

 

13.0%

 

12.6%

 

11.5%

1 10.12.1997

BB BIOTECH AG (MILAN)-EUR


Rolling performance

 

 

SHARE

 

NAV

 

NBI TR

30.09.2021 – 30.09.2022

 

(26.3%)

 

(13.9%)

 

(11.7%)

30.09.2020 – 30.09.2021

 

30.6%

 

24.5%

 

21.8%

30.09.2019 – 30.09.2020

 

17.2%

 

22.0%

 

27.3%

28.09.2018 – 30.09.2019

 

(6.3%)

 

(10.0%)

 

(12.6%)

29.09.2017 – 28.09.2018

 

15.9%

 

0.6%

 

12.1%

Annual performance

 

 

SHARE

 

NAV

 

NBI TR

2021

 

13.0%

 

(7.8%)

 

7.4%

2020

 

19.7%

 

24.8%

 

16.1%

2019

 

22.6%

 

28.1%

 

27.6%

2018

 

(1.3%)

 

(11.1%)

 

(4.3%)

2017

 

12.2%

 

12.5%

 

6.7%

Cumulated performance

30.09.2022

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

(22.8%)

 

(3.3%)

 

(6.7%)

1 year

 

(26.3%)

 

(13.9%)

 

(11.7%)

3 years

 

12.8%

 

30.9%

 

37.0%

5 years

 

22.6%

 

18.6%

 

34.2%

10 years

 

459%

 

328%

 

250%

since inception 1)

 

376%

 

344%

 

177%

1 19.10.2000

Annualized performance

30.09.2022

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

(26.3%)

 

(13.9%)

 

(11.7%)

3 years

 

4.1%

 

9.4%

 

11.1%

5 years

 

4.1%

 

3.5%

 

6.1%

10 years

 

18.8%

 

15.6%

 

13.3%

since inception 1)

 

7.4%

 

7.0%

 

4.8%

1 19.10.2000

Multi-year comparison

 

 

30.09.2022

 

2021

 

2020

 

2019

 

2018

 

 

Market capitalization at the end of the period (in CHF mn)

 

2 919.6

 

4 274.1

 

4 107.9

 

3 670.3

 

3 235.4

 

highchart-toggle

Net Asset Value at the end of the period (in CHF mn)

 

2 721.3

 

3 283.5

 

3 887.5

 

3 393.0

 

2 884.5

 

highchart-toggle

Number of shares (in mn)

 

55.4

 

55.4

 

55.4

 

55.4

 

55.4

 

highchart-toggle

Trading volume (in CHF mn)

 

1 296.7

 

2 101.0

 

2 315.6

 

2 004.2

 

2 610.7

 

highchart-toggle

Profit/(loss) (in CHF mn)

 

(322.6)

 

(404.8)

 

691.2

 

677.4

 

(471.3)

 

highchart-toggle

Closing price at the end of the period in CHF

 

52.70

 

77.15

 

74.15

 

66.25

 

58.40

 

highchart-toggle

Closing price (G) at the end of the period in EUR

 

54.30

 

74.05

 

68.00

 

61.40

 

52.00

 

highchart-toggle

Closing price (I) at the end of the period in EUR

 

54.30

 

74.40

 

68.50

 

61.00

 

52.00

 

highchart-toggle

Stock performance (incl. distributions) 1)

 

(27.7%)

 

8.3%

 

19.3%

 

18.5%

 

(5.2%)

 

highchart-toggle

High/low share price in CHF

 

78.15/51.00

 

92.20/73.40

 

74.70/45.44

 

73.20/59.35

 

74.10/56.10

 

highchart-toggle

High/low share price in EUR

 

75.40/49.60

 

86.20/67.80

 

69.00/43.04

 

64.70/52.10

 

64.80/48.60

 

highchart-toggle

Premium/(discount) (annual average)

 

24.2%

 

19.5%

 

9.2%

 

11.8%

 

9.7%

 

highchart-toggle

Dividend in CHF

 

N.A.

 

3.85

 

3.60

 

3.40

 

3.05

 

highchart-toggle

Degree of investment (quarterly figures)

 

112.5%

 

108.6%

 

106.8%

 

109.1%

 

108.4%

 

highchart-toggle

Total Expense Ratio (TER) p.a. 2)

 

1.27%

 

1.22%

 

1.25%

 

1.26%

 

1.25%

 

highchart-toggle

1 All figures in CHF %, total return-methodology

2 Based on market capitalization

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer